Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Alumis Inc. Common StockNASDAQ: ALMS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns negative
Q2 FY2026 net income was -$142.22M, compared with $59.32M a year earlier. Trailing-twelve-month net income was -$438.96M. Over 3 fiscal years it compounded at +29.5% a year.
Context
- Net income amounted to 1011.7% of revenue in FY2025.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$2.77B (+1036.6%) for the fiscal year ending Dec 2026, a step up from the -17.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$142.22M+52.8% QoQ
- Last fiscal yearDec 2025
- -$243.33M-17.3% YoY
- LTMJun 2026
- -$438.96M+92.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -339.7% | -11.5% | +328.2 pp |
| 1 year | -17.3% | +1036.6% | +1053.9 pp |
| 3-year CAGR | +29.5% | +87.3% | +57.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (243.33M) USD
- Year-over-year change
- +17.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (243.33M) | +17.3% |
| FY2024 | 2024-12-31 | (294.23M) | -89.8% |
| FY2023 | 2023-12-31 | (154.99M) | -38.5% |
| FY2022 | 2022-12-31 | (111.93M) | — |
Net Income vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +92.9% is the 3rd highest of 9, against a peer median of -27.2%.
- Net income amounts to 5933.5% of revenue for ALMS, versus a peer median of 832.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M USD | +92.9% | +29.5% | 5933.5% |
| LTM Mar 2026 | $364.23M USD | +879.7% | — | 121.5% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M USD | +21.4% | +12.6% | — |
| LTM Mar 2026 | $84.74M USD | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $69.66M USD | -46.5% | -9.3% | 832.6% | |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $27.37M USD | -52.6% | -18.3% | — | |
| LTM Mar 2026 | $26.79M USD | -81.0% | — | 11.5% | |
| FY2025 | $18.43M USD | +94.4% | +13.7% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -27.2% | +13.1% | 832.6% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| Deferred Income Tax | 0 | 0 | 0 | (8.56M) |
| Stock-Based Compensation | 5.96M | 8.63M | 19.46M | 43.52M |
| Change in Working Capital | (1.92M) | 12.06M | 14.76M | 26.32M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.29M | (642K) | 8.51M | (6.04M) |
| Other Working Capital | (3.21M) | 12.7M | 6.25M | 32.35M |
| Other Non-Cash Items | (86K) | 3.05M | 1.79M | (190.98M) |
| Operating Cash Flow | (107.72M) | (129.98M) | (255.08M) | (369.52M) |
| Capital Expenditures | (2.41M) | (4.5M) | (1.73M) | (653K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (209.08M) | (11.28M) | (240.06M) | (209.17M) |
| Sales of Investments | 142.73M | 76.25M | 128M | 447.96M |
| Other Investing Activities | 0 | 0 | 0 | 49.74M |
| Investing Cash Flow | (68.75M) | 60.47M | (113.79M) | 287.88M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 193.32M | 2.08M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.73M | (96K) | 40.59M | 0 |
| Financing Cash Flow | 101.63M | 89.68M | 492.37M | 2.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (74.85M) | 20.18M | 123.5M | (79.58M) |
| Free Cash Flow | (110.13M) | (134.47M) | (256.81M) | (370.18M) |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.